signaling gateway home
registrationelectronic alerthelpcontact ussite guidesearch
cell signaling update signaling update home updates  news  research library featured articles conferences

Autoimmunity: Gene therapy for diabetes

home | subscribe

Expression of diabetes-resistant MHC class II alleles by non-obese diabetic (NOD) mice is sufficient to prevent the development of diabetes.

Type 1 diabetes mellitus (T1DM) occurs as a result of T-cell-mediated destruction of the insulin-producing beta-cells in the pancreas. Non-obese diabetic (NOD) mice, which spontaneously develop diabetes, are a useful model system of this disease. In this study, the authors show that expression of diabetes-resistant MHC class II alleles by NOD mice — using retroviral transduction of autologous bone-marrow cells — is sufficient to prevent the development of diabetes.

In humans, the development of T1DM is associated with the inheritance of particular MHC class II alleles that lack a charged amino acid at position 57 of the beta-chain. In NOD mice, the single MHC class II allele present is I–Ag7, which also lacks a charged residue at position 57. It is thought that lack of a charged residue at this position prevents the formation of a salt bridge between the alpha- and beta-chains of the MHC class II molecule, which could affect the ability of these molecules to mediate negative selection of autoreactive T cells.

Previous studies using transgenic mice and allogeneic bone-marrow chimeras have shown that it is possible to prevent diabetes in NOD mice, but it has not been possible to determine the preventative mechanism.

Retroviral constructs with green fluorescent protein fused to the cytoplasmic tails of diabetes-resistant I–A beta-chains (which have a charged residue at position 57) were shown to be expressed at the cell surface of MHC-class-II-positive cells and could pair with endogenous alpha-chains. Young NOD mice were lethally irradiated and transplanted with bone marrow retrovirally transduced with the I–Abeta constructs, and their blood-glucose levels were monitored each week. All of the mice were protected from diabetes, compared with four of six mice that received bone marrow transfected with a control construct. Even when diabetes was aggressively induced using cyclophosphamide, the mice that received I–Abeta-transduced bone marrow were resistant to the development of diabetes for up to 46 weeks after transfer, and the level of insulitis was reduced.

To address the mechanism of resistance, the authors used enzyme-linked immunosorbent spot (ELISPOT) assays to look at the frequency of T cells that produced cytokines in response to peptide 206–220 from glutamic-acid decarboxylase, an immunodominant self-antigen peptide in NOD mice. No cytokine production was detectable in NOD mice that received I-Abeta-transduced bone marrow, indicating that self-reactive T cells had been functionally inactivated or eliminated. To determine whether this was owing to deletion of self-reactive T cells in the thymus or to peripheral tolerance, the authors used I–Ag7 tetramers loaded with a peptide known to stimulate pancreatic-islet-reactive T-cell clones. The frequency of CD4+ T cells labelled with the tetramer was significantly reduced among thymocytes from NOD mice reconstituted with I–Abeta-transduced cells compared with NOD mice that received cells transduced with the control construct, supporting the idea that I–Abeta mediated the removal of self-reactive T cells by negative selection.

This study offers the prospect that T1DM could be prevented by providing susceptible individuals with protective MHC class II alleles, using autologous bone marrow. This approach would be preferable to the use of allogeneic cells, because graft-versus-host disease would be avoided and it might be possible to use milder conditioning regimens before transplantation.


Elaine Bell

References

  1. Tian, C. et al. Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. 114, 969–978 (2004).Article | PubMed |
  2. Creusot, R. E. & Fathman, C. G. Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. J. Clin. Invest. 114, 892–894 (2004).Article | PubMed |

Links

WEB SITE
John Iacomini's homepage

more more stories

 Nature Publishing Group

HOME | SIGNALING UPDATE | MOLECULE PAGES | DATA CENTER | ABOUT US
registration | e-alert | help | contact us | site guide | search

© 2002-2009 Nature Publishing Group

Privacy Policy